| CD19+ CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation F Flores-Borja, A Bosma, D Ng, V Reddy, MR Ehrenstein, DA Isenberg, ... Science translational medicine 5 (173), 173ra23-173ra23, 2013 | 755 | 2013 |
| Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples V Reddy, C Klein, DA Isenberg, MJ Glennie, G Cambridge, MS Cragg, ... Rheumatology 56 (7), 1227-1237, 2017 | 158 | 2017 |
| B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumaband implications for study design V Reddy, D Jayne, D Close, D Isenberg Arthritis research & therapy 15, 1-16, 2013 | 130 | 2013 |
| Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus V Reddy, G Cambridge, DA Isenberg, MJ Glennie, MS Cragg, M Leandro Arthritis & rheumatology 67 (8), 2046-2055, 2015 | 93 | 2015 |
| B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? P Mehta, JC Porter, RC Chambers, DA Isenberg, V Reddy The Lancet Rheumatology 2 (10), e589-e590, 2020 | 75 | 2020 |
| Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long‐term effects on serum immunoglobulins V Reddy, L Martinez, DA Isenberg, MJ Leandro, G Cambridge Arthritis care & research 69 (6), 857-866, 2017 | 58 | 2017 |
| Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? V Reddy, LN Dahal, MS Cragg, M Leandro Drug discovery today 21 (8), 1330-1338, 2016 | 49 | 2016 |
| CD24 expression and B cell maturation shows a novel link with energy metabolism: potential implications for patients with myalgic encephalomyelitis/chronic fatigue syndrome FFK Mensah, CW Armstrong, V Reddy, AS Bansal, S Berkovitz, ... Frontiers in immunology 9, 2421, 2018 | 46 | 2018 |
| Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study F Mensah, A Bansal, S Berkovitz, A Sharma, V Reddy, MJ Leandro, ... Clinical & Experimental Immunology 184 (2), 237-247, 2016 | 36 | 2016 |
| Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus V Reddy, S Croca, D Gerona, I De La Torre, D Isenberg, V McDonald, ... Rheumatology 52 (5), 951-952, 2013 | 29 | 2013 |
| Lupus and leg ulcers—a diagnostic quandary V Reddy, M Dziadzio, S Hamdulay, S Boyce, N Prasad, A Keat Clinical rheumatology 26, 1173-1175, 2007 | 28 | 2007 |
| Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis P Mota, V Reddy, D Isenberg Expert review of clinical immunology 13 (7), 667-676, 2017 | 24 | 2017 |
| A still image of a transient rash captured by a mobile phone M Dziadzio, S Hamdulay, V Reddy, S Boyce, A Keat, J Andrews Clinical rheumatology 26, 979-980, 2007 | 22 | 2007 |
| Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab? VR Reddy, RJ Pepper, K Shah, G Cambridge, SR Henderson, C Klein, ... Rheumatology 61 (7), 2894-2904, 2022 | 18 | 2022 |
| Anti-CD20 monoclonal antibodies in systemic lupus erythematosus K Shah, M Cragg, M Leandro, V Reddy Biologicals 69, 1-14, 2021 | 17 | 2021 |
| Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020 C Norris-Grey, G Cambridge, S Moore, V Reddy, M Leandro Rheumatology 61 (2), 591-596, 2022 | 13 | 2022 |
| Detection of experimental and clinical immune complexes by measuring SHIP-1 recruitment to the inhibitory FcγRIIB RJ Stopforth, RJ Oldham, AL Tutt, P Duriez, HT Chan, BF Binkowski, ... The Journal of Immunology 200 (5), 1937-1950, 2018 | 12 | 2018 |
| Obinutuzumab outperforms rituximab at inducing b-cell cytotoxicity in vitro through fc-mediated effector mechanisms in rheumatoid arthritis and systemic lupus erythematosus V Reddy, C Klein, DA Isenberg, G Cambridge, M Glennie, M Cragg, ... Arthritis & Rheumatology 67, 2015 | 10 | 2015 |
| Is TNFα really a good therapeutic target in motoneuronal degeneration? A case of amyotrophic lateral sclerosis in a patient with RA receiving infliximab M Dziadzio, V Reddy, S Rahman, C Mummery, A Keat Rheumatology 45 (11), 1445-1446, 2006 | 10 | 2006 |
| Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice P Mehta, K Meeran, E Macphie, A Abbas, J Rippin, RC Jeffery, V Reddy, ... The Lancet Rheumatology 3 (2), e92-e94, 2021 | 9 | 2021 |
Mark CraggCentre for Cancer Immunology, University of Southampton在 soton.ac.uk 的电子邮件经过验证
